Growth Metrics

Acro Biomedical (ACBM) Amortization of Deferred Charges (2022 - 2023)

Acro Biomedical's quarterly Amortization of Deferred Charges came in at $3.1 million in Q2 2023, down 20.48% year-on-year from $3.9 million in Q2 2022, and down 20.48% quarter-over-quarter from $3.9 million in Q1 2023.

Acro Biomedical has reported Amortization of Deferred Charges for 2 years, with the latest figure at $3.1 million in Q2 2023.

  • For the quarter ending Q2 2023, Amortization of Deferred Charges fell 20.48% year-over-year to $3.1 million; the trailing twelve-month figure through Jun 2023 stood at $14.9 million (changed N/A YoY), and the FY2022 full-year result was $15.7 million, up 105.35% from the prior year.
  • Amortization of Deferred Charges for Q2 2023 stood at $3.1 million, down from $3.9 million in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $3.9 million in Q1 2022, with the low at $3.1 million in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn -
2 Berto Acquisition 316.66 Mn 316.66 Mn -
3 Centurion Acquisition 311.94 Mn 311.94 Mn -
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn -
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn -
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn -
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn -
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn -
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn -
10 Acro Biomedical - - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 3.12 Mn
Jun 30, 2023 3.12 Mn
Mar 31, 2023 3.93 Mn
Mar 31, 2023 3.93 Mn
Jun 30, 2022 3.93 Mn
Jun 30, 2022 3.93 Mn
Mar 31, 2022 3.93 Mn
Mar 31, 2022 3.93 Mn